Abstract:The discovery and advances of medicines may be considered as the ultimate relevant translational science effort that adds to human invulnerability and happiness. But advancing a fresh medication is a quite convoluted, costly, and protracted operation, normally costing USD ~2.6 billion and consuming a mean time span of 12 years. Methods to cut back expenditure and hasten new drug discovery have prompted an arduous and compelling brainstorming exercise in the pharmaceutical industry. The engagement of Artificial Intelligence (AI), including the deep-learning (DL) component in particular, has been facilitated by the employment of classified big data, in concert with strikingly reinforced computing prowess and cloud storage, across all fields. AI has energized computer-facilitated drug discovery. An unrestricted espousing of machine learning (ML), especially DL, in many scientific specialties, and the technological refinements in computing hardware and software, in concert with various aspects of the problem, sustain this progress. ML algorithms have been extensively engaged for computer-facilitated drug discovery. DL methods, such as artificial neural networks (ANNs) comprising multiple buried processing layers, have of late seen a resurgence due to their capability to power automatic attribute elicitations from the input data, coupled with their ability to obtain nonlinear input-output pertinencies. Such features of DL methods augment classical ML techniques which bank on human-contrived molecular descriptors. A major part of the early reluctance concerning utility of AI in pharmaceutical discovery has begun to melt, thereby advancing medicinal chemistry. AI, along with modern experimental technical knowledge, is anticipated to invigorate the quest for new and improved pharmaceuticals in an expeditious, economical, and increasingly compelling manner. DL-facilitated methods have just initiated kickstarting for some integral issues in drug discovery. Many technological advances, such as "message-passing paradigms", "spatial-symmetry-preserving networks", "hybrid de novo design", and other ingenious ML exemplars, will definitely come to be pervasively widespread and help dissect many of the biggest, and most intriguing inquiries. Open data allocation and model augmentation will exert a decisive hold during the progress of drug discovery employing AI. This review will address the impending utilizations of AI to refine and bolster the drug discovery operation.

Augmenting DMTA using predictive AI modelling at AstraZeneca

Advances of AI-driven Drug Design and Discovery in Pharmaceuticals - Review

Accelerating Pharmaceutical Research and Development through AI-Driven Drug Discovery

AMPL: A Data-Driven Modeling Pipeline for Drug Discovery

Perspectives on the use of machine learning for ADME prediction at AstraZeneca

Artificial Intelligence for Autonomous Molecular Design: A Perspective

Evaluation Framework for AI-driven Molecular Design of Multi-target Drugs: Brain Diseases as a Case Study

Retro Drug Design: From Target Properties to Molecular Structures

Artificial Intelligence for Drug Discovery: Are We There Yet?

AI-based Computational Methods in Early Drug Discovery and Post Market Drug Assessment: A Survey

The Process of AI-Aided Drug Design

AI in drug development: a multidisciplinary perspective

Artificial Intelligence in De novo Drug Design: Are We Still There?

The AI-driven Drug Design (AIDD) platform: an interactive multi-parameter optimization system integrating molecular evolution with physiologically based pharmacokinetic simulations

Application of Artificial Intelligence and Machine Learning in Drug Discovery and Development

Artificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development

Exploring Novel Biologically-Relevant Chemical Space Through Artificial Intelligence: The NCATS ASPIRE Program

An AI Model for Predicting New Anticancer Molecules

Designing an adaptive learning framework for predicting drug-target affinity using reinforcement learning and graph neural networks

MTAF–DTA: multi-type attention fusion network for drug–target affinity prediction

De Novo Drug Design Using Transformer-Based Machine Translation and Reinforcement Learning of an Adaptive Monte Carlo Tree Search